Rate My Professor James Galloway

Professor James Galloway, MBChB, MSc, PhD, serves as the Arthritis UK Professor of Rheumatology and Versus Arthritis Endowed Chair at King's College London in the Faculty of Life Sciences & Medicine. An Honorary Consultant Rheumatologist at King’s College Hospital NHS Foundation Trust, he completed his PhD in the Versus Arthritis-funded Epidemiology Unit at the University of Manchester prior to his appointment as Clinical Lecturer at King's College London. Currently, he is Senior Director for the MBBS Programme within the GKT School of Medical Education and Programme Director for the PGCert in Applied Research Methods in the Integrated Academic Training programme. Galloway co-directs the Centre for Rheumatic Diseases in the School of Immunology & Microbial Sciences and leads the Galloway & Norton Group, a clinical epidemiology and trials team specializing in immune-mediated rheumatic diseases. His research leverages large-scale real-world health data, advanced biostatistics, and pragmatic trials to evaluate treatment safety, optimize therapeutic strategies, address health inequalities, and study rare diseases including sarcoidosis, IgG4-related disease, and VEXAS syndrome.

Galloway's contributions include key publications such as 'Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)' (Annals of the Rheumatic Diseases, 2010), 'Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment' (Rheumatology, 2011), 'A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis' (Rheumatology, 2019), and contributions to RECOVERY trial analyses on COVID-19 treatments (The Lancet, 2021). He has influenced clinical practice through contributions to British Society for Rheumatology and EULAR guidelines, leadership in the National Early Inflammatory Arthritis Audit as methodology lead, and a successful campaign with NRAS and BSR that prompted NICE guidance changes for earlier anti-TNF access in 2021. Galloway holds national roles as Chief Medical Advisor to the National Rheumatoid Arthritis Society and Deputy Editor of Rheumatology, with over 19,000 citations reflecting his impact on pharmacovigilance, treatment outcomes, and health disparities in rheumatology.